{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:46:34Z","timestamp":1791215194937,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Between 2011 and 2015, Men who have sex with men (MSM) accounted for nearly half of new HIV cases among men in Israel. This study carries out a cost-utility analysis of PrEP (HIV Pre Exposure Prophylaxis), an antiretroviral medication that can protect against the acquisition of HIV infection, whose incidence rate in Israel is around 1.74 per 1000 MSM.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Method<\/jats:title>\n<jats:p>Epidemiological, demographic, health service utilisation and economic data were integrated into a spread-sheet model in order to calculate the cost per averted disability-adjusted life year (DALY) of the intervention from a societal perspective, in mid-2018 US$ using a 3% discount rate. Cost utility analyses were performed for both types of PrEP delivery (continuous regimen and on-demand), together with sensitivity analyses on numbers of condom users who take up PrEP (baseline 25%) and subsequently abandon condom use (baseline 75%), PrEP efficacy (baseline 86%), PrEP prices and monitoring costs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Around 21.3% of MSM are high risk (as defined by having unprotected anal intercourse). Offering PrEP to this group would have a ten year net cost of around 1563 million USD, preventing 493 persons from becoming HIV-positive, averting around 1616 DALYs at a cost per averted DALY of around 967,744 USD. This will render the intervention to be not cost-effective. PrEP drug prices would have to fall dramatically (by 90.7%) for the intervention to become cost-effective (i.e. having a cost per averted DALY less than thrice GNP per capita) in Israel. PrEP remains not cost-effective (at 475,673 USD per averted DALY) even if intervention costs were reduced by using an \u201con demand\u201d instead of a daily schedule. Even if there were no changes in condom use, the resultant 411,694 USD cost-utility ratio is still not cost-effective.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Despite PrEPs high effectiveness against HIV, PrEP was found not to be cost-effective in the Israeli context because of a combination of relatively low HIV incidence, high PrEP costs, with a likelyhood that some low-risk MSM (ie: who use condoms) may well begin taking PrEP and as a consequence many of these will abandon condom use. Therefore, ways of minimizing these last two phenomena need to be found.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12889-020-8334-4","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T10:02:32Z","timestamp":1582797752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6756-1900","authenticated-orcid":false,"given":"G. M.","family":"Ginsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Chemtob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"8334_CR1","doi-asserted-by":"crossref","unstructured":"Chemtob D, Mor Z, Harel N, Averick N. HIV Infection among Men Having Sex with Men in Israel: Thirty-five years of Epidemiological Trends and Clinical Characteristics.\u00a0BMC Public Health. 2019;19:747.","DOI":"10.1186\/s12889-019-7000-1"},{"issue":"27","key":"8334_CR2","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399.","journal-title":"N Engl J Med"},{"key":"8334_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399\u2013410.","journal-title":"N Engl J Med"},{"key":"8334_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","volume":"387","author":"S McCormack","year":"2016","unstructured":"McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53\u201360.","journal-title":"Lancet."},{"key":"8334_CR5","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"JM Molina","year":"2015","unstructured":"Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand Preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237\u201346.","journal-title":"N Engl J Med"},{"key":"8334_CR6","volume-title":"Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015."},{"key":"8334_CR7","first-page":"53","volume-title":"Developing evidence based policy for implementing HIV pre exposure prophylaxis (PrEP) in Israel \u2013 preliminary recommendations of the ad hoc advisory committee","author":"D Chemtob","year":"2016","unstructured":"Chemtob D, Harel N, Hovers M, Yust I, Livnat Y, Levy I, et al. Developing evidence based policy for implementing HIV pre exposure prophylaxis (PrEP) in Israel \u2013 preliminary recommendations of the ad hoc advisory committee. Ramat Gan: Annual Conference of the Society of Public Health Physicians in Israel and the Schools of Public Health; June 2016. p. 53."},{"key":"8334_CR8","doi-asserted-by":"publisher","unstructured":"Ginsberg GM, Shinhar E, Kopel E, Chemtob D. Should Men who have sex with Men be allowed to donate blood in Israel? Israel Journal of Health Policy Research. 2016; 5:60 DOI https:\/\/doi.org\/10.1186\/s13584-016-0123-22016; 5:51.","DOI":"10.1186\/s13584-016-0123-22016"},{"key":"8334_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1186\/s12879-017-2782-1","volume":"17","author":"Z Mor","year":"2017","unstructured":"Mor Z, Turner D, Livnat Y, Levy I. HIV infected men who have sex with men in Israel: knowledge, attitudes and sexual behavior. BMC Infect Dis. 2017;17:679. https:\/\/doi.org\/10.1186\/s12879-017-2782-1.","journal-title":"BMC Infect Dis"},{"key":"8334_CR10","unstructured":"Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C et al. for the ANRS IPERGAY Study Group. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV 2017 Published Online July 23, 2017 http:\/\/dx.doi.org\/10.1016\/ S2352\u20133018(17)30089\u20139 See Online\/Comment http:\/\/dx.doi.org23."},{"issue":"5","key":"8334_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2165\/00019053-199610050-00003","volume":"10","author":"MA Koopmanschap","year":"1996","unstructured":"Koopmanschap MA, Rutten FFH. A practical guide for estimating indirect cost of disease. Pharmacoeconomics. 1996;10(5):460\u20136.","journal-title":"Pharmacoeconomics"},{"key":"8334_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423\u201334.","journal-title":"N Engl J Med"},{"key":"8334_CR13","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","volume":"381","author":"K Choopanya","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the BangkokTenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083\u201390.","journal-title":"Lancet"},{"key":"8334_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","volume":"372","author":"JM Marrazzo","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509\u201318.","journal-title":"N Engl J Med"},{"key":"8334_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/QAI.0000000000000365","volume":"67","author":"W Spreen","year":"2014","unstructured":"Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr. 2014;67:487\u201392.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"8334_CR16","unstructured":"Israel Ministry of Health. Ministry of Health Price List for Ambulatory and Hospitalization Services. https:\/\/www.health.gov.il\/Subjects\/Finance\/Taarifon\/Pages\/PriceList.aspx Accessed 22nd April 2018."},{"key":"8334_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1059\/0003-4819-156-8-201204170-00001","volume":"156","author":"JL Juusola","year":"2012","unstructured":"Juusola JL, Juusola MS, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of Preexposure prophylaxis for HIV prevention in men who have sex with men in the United States. Ann Intern Med. 2012;156:541\u201350. https:\/\/doi.org\/10.1059\/0003-4819-156-8-201204170-00001.","journal-title":"Ann Intern Med"},{"key":"8334_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1310\/48ET-TT7G-35RA-D4C3","volume":"2","author":"AH Miners","year":"2002","unstructured":"Miners AH, Sabin CA, Mocroft A, Youle M, Fisher M, Johnson M. Health-related quality of life in individuals infected with HIV in the era of HAART. HIV Clin Trials. 2002;2:484\u201392.","journal-title":"HIV Clin Trials"},{"key":"8334_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115511","volume":"10","author":"BL Jewell","year":"2015","unstructured":"Jewell BL, Cremin I, Pickles M, Celum C, Baeten JM, Delany-Moretlwe S, et al. Estimating the cost-effectiveness of pre-exposure prophylaxis to ReduceHIV-1 and HSV-2 incidence in HIV-Serodiscordant couples in SouthAfrica. PLoS One. 2015;10:e0115511. https:\/\/doi.org\/10.1371\/journal.pone.0115511.","journal-title":"PLoS One"},{"issue":"10","key":"8334_CR20","doi-asserted-by":"publisher","first-page":"e108742","DOI":"10.1371\/journal.pone.0108742","volume":"9","author":"Anders Chen","year":"2014","unstructured":"Chen A, Dowdy DW. Clinical Effectiveness and Cost-Effectiveness of HIV PreExposure Prophylaxis in Men Who Have Sex with Men: Risk Calculators for Real-World Decision-Making. PLOS ONE 2014; 9: 10. e108742.","journal-title":"PLoS ONE"},{"key":"8334_CR21","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1093\/cid\/ciw578","volume":"6311","author":"JW Drabo","year":"2016","unstructured":"Drabo JW, Hay RV, Wagner ZR, Sood N. Cost-effectiveness analysis of Preexposure prophylaxis for the prevention of HIVAmongLosAngelesCountyMen who have sex with men Emmanuel F. Clin Infect Dis. 2016;6311:1495\u2013504.","journal-title":"Clin Infect Dis"},{"key":"8334_CR22","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/bmj.301.6762.1183","volume":"301","author":"GW Rutherford","year":"1990","unstructured":"Rutherford GW, Lifson AR, Hessol NA, et al. Course of HIV-1 infection in a cohort of homosexual and bisexual men: an 11 year follow up study. BMJ. 1990;301:1183\u20138.","journal-title":"BMJ."},{"key":"8334_CR23","unstructured":"Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D et al. for the HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS) and the Concerted Action on Sero-Conversion to AIDS and Death in Europe (CASCADE) Collaboration. Current CD4 Cell Count and the Short-Term Risk of AIDS and Death before the Availability of Effective Antiretroviral Therapy in HIV-Infected Children and Adults Jnl Infect Dis 2008;197:398\u2013404."},{"issue":"12","key":"8334_CR24","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1093\/cid\/cit158","volume":"56","author":"Neeraj Sood","year":"2013","unstructured":"Sood N, Wagner Z, Jaycocks A, Drabo E, Vardavas R. Test-and-Treat in Los Angeles: A Mathematical Model of the Effects of Test-and-Treat for the Population of Men Who Have Sex With Men in Los Angeles County. Clin Infect Dis 2013;56: 1789\u20131796. Supplementary Appendix. Published online 2013 Mar 13. doi: https:\/\/doi.org\/10.1093\/cid\/cit158","journal-title":"Clinical Infectious Diseases"},{"key":"8334_CR25","doi-asserted-by":"crossref","unstructured":"Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiebaut R, et al. on behalf of the CASCADE Collaboration in EuroCoorda. Time From Human Immunodeficiency Virus Seroconversion to Reaching CD41 Cell Count Thresholds ,200, 350, and 500 Cells\/mm3: Assessment of Need Following Changes in Treatment Guidelines. Clin Infect Dis 2011;53:817\u2013825.","DOI":"10.1093\/cid\/cir494"},{"key":"8334_CR26","doi-asserted-by":"publisher","unstructured":"The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008:26::293\u20139. doi:https:\/\/doi.org\/10.1016\/S0140-6736(08)61113-7.","DOI":"10.1016\/S0140-6736(08)61113-7"},{"key":"8334_CR27","doi-asserted-by":"publisher","unstructured":"The Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies AIDS. 2007; 21: 1185\u201397. doi:https:\/\/doi.org\/10.1097\/QAD.0b013e328133f285.","DOI":"10.1097\/QAD.0b013e328133f285"},{"key":"8334_CR28","doi-asserted-by":"publisher","unstructured":"Nichols BE, Boucher CAB, van der Valk M, Rijnders BJA, van de Vijver DAMC. Cost-eff ectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. Lancet Infect Dis 2016; 16: 1423\u201329 https:\/\/doi.org\/10.1016\/S1473-3099 (16)30311\u20135 See Comment page 1316.","DOI":"10.1016\/S1473-3099"},{"key":"8334_CR29","doi-asserted-by":"crossref","unstructured":"Ross EL, Cinti SK,Hutton DW. A cost-effective, clinically actionable strategy for targeting HIV preexposure prophylaxis to high-risk men who have sex with men. Journal of Acquired Immune Deficiency Syndromes 2016; 72: e61-e67. Supplementary Appendix.","DOI":"10.1097\/QAI.0000000000000987"},{"key":"8334_CR30","doi-asserted-by":"publisher","unstructured":"Chemtob D, Op de Coul E, van Sighem A, Mor Z, Cazein F, Semaille C Impact of Male Circumcision among heterosexual HIV cases: comparisons between three low HIV prevalence countries Isr J Health Policy Res 2015; 4:36. doi: https:\/\/doi.org\/10.1186\/s13584-015-0033-8. eCollection 2015.","DOI":"10.1186\/s13584-015-0033-8"},{"key":"8334_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13584-017-0141-8","volume":"6","author":"D Chemtob","year":"2017","unstructured":"Chemtob D, Gandacu D, Mor Z, Grotto I, Anis E, Rosenberg E. A national strategic plan for reducing the burden of sexually transmitted infections in Israel by the year 2025. Isr J of Health Policy Res. 2017;6:23. https:\/\/doi.org\/10.1186\/s13584-017-0141-8.","journal-title":"Isr J of Health Policy Res"},{"key":"8334_CR32","doi-asserted-by":"crossref","unstructured":"Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; CD003255.","DOI":"10.1002\/14651858.CD003255"},{"issue":"3","key":"8334_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/infdis\/jir747","volume":"205","author":"James P. Hughes","year":"2012","unstructured":"Hughes JP, Baeten JM, Lingappa JR, Margaret AS, Wald A, de Bruyn G et al. Determinants of per coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Imfect Dis 2012;205:358\u2013365. https:\/\/doi.org\/10.1093\/infdis\/jir747 PMID: 2241800 Accessed 19th April 2018.","journal-title":"The Journal of Infectious Diseases"},{"key":"8334_CR34","doi-asserted-by":"crossref","unstructured":"Sagaon-Teyssier, L. Suzan-Monti, M. Demoulin, B. Capitant, C. Lorente, N. Preau, M \u2026 . Spire, B. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial. AIDS Care 2016; 28.","DOI":"10.1080\/09540121.2016.1146653"},{"key":"8334_CR35","unstructured":"Molina, JM. Charreua, I. Spire, B. Cotte, L. Chas, J. Capitant, C. Efficacy, safety, and effect on sexual behavior of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. The Lancet HIV 2017; 4(9): E402-E410."},{"issue":"4","key":"8334_CR36","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1540-5982.2008.00502.x","volume":"41","author":"Christopher S. Carpenter","year":"2008","unstructured":"Carpenter CS. Sexual orientation, work, and income in Canada. Can J Econ 2008;41:1239\u201361\/10.1016\/ S2352\u20133018(17)30088\u20137.","journal-title":"Canadian Journal of Economics\/Revue canadienne d'\u00e9conomique"},{"key":"8334_CR37","unstructured":"Central Bureau of Statistics. Labour Force Survey Quarterly Jan \u2013 March 2018, No. 2018\/1, April 2018, Jerusalem, Israel."},{"key":"8334_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1155\/2015\/964512","volume":"26","author":"E Ouellet","year":"2015","unstructured":"Ouellet E, Durand M, Guertin JR, LeLorier J, Tremblay CL. Cost effectiveness of \u2018on demand\u2019 HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada. Can J Infect Dis Med Microbiol. 2015;26:23\u20139.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"8334_CR39","unstructured":"Central Bureau of Statistics, Statistical Abstract of Israel 2017, Jerusalem 2018. http:\/\/www.cbs.gov.il\/reader\/shnatonenew_site.htm accessed 22nd April 2018."},{"key":"8334_CR40","doi-asserted-by":"publisher","unstructured":"Cambiano V, Miners A, Dunn D, et al. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation. Lancet Infect Dis 2016; published online Oct 17. https:\/\/doi.org\/10.1016\/S1473-3099 (17)30540-6.","DOI":"10.1016\/S1473-3099"},{"key":"8334_CR41","unstructured":"WHO. World Health Organization, Cost-Effectiveness Thresholds. http:\/\/www.who.int\/choice\/costs\/CER_thresholds\/en\/index.html 2012 [April 30, 2012]."},{"key":"8334_CR42","unstructured":"Central Bureau of Statistics. Monthly Bulletin of Statistics,Jerusalem March 2018. http:\/\/cbs.gov.il\/webpub\/pub\/text_page_eng.html?publ=93&Cyear=2018&Cmonth=3"},{"key":"8334_CR43","unstructured":"Central Bureau of Statistics. Macro-Economics Statistics Quarterly 2017, http:\/\/cbs.gov.il\/webpub\/pub\/text_page_eng.html?publ=41&Cyear=2017&Cmonth =10 accessed 22nd April 2018."},{"key":"8334_CR44","unstructured":"Bank of Israel. Macro-Economic forecasts. http:\/\/www.boi.org.il\/en\/Research\/RegularReports\/Pages\/ResearchForcast.aspx Accessed 22nd April 2018."},{"key":"8334_CR45","first-page":"2001","volume-title":"Macroeconomics and health: investing in health for economic development","author":"WHO Commission on MacroEconomics and Health","year":"2001","unstructured":"WHO Commission on MacroEconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001. p. 2001."},{"key":"8334_CR46","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, Claxton KP. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19:929\u201335.","journal-title":"Value Health"},{"issue":"10","key":"8334_CR47","doi-asserted-by":"publisher","first-page":"e1001323","DOI":"10.1371\/journal.pmed.1001323","volume":"9","author":"Gabriela B. Gomez","year":"2012","unstructured":"Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, Garnett GP et al. The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study. PLoS Med 9(10): e1001323. doi:https:\/\/doi.org\/10.1371\/journal.pmed.1001323|.","journal-title":"PLoS Medicine"},{"key":"8334_CR48","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/cid\/cit946","volume":"58","author":"K Schneider","year":"2014","unstructured":"Schneider K, Gray RT, Wilson DP. A cost-effectiveness analysis of HIV Preexposure prophylaxis for men who have sex with men in Australia. Clinical Infect Dis. 2014;58:1027\u201334.","journal-title":"Clinical Infect Dis"},{"key":"8334_CR49","doi-asserted-by":"publisher","unstructured":"Ong KJ, Desai S, Field N, Desai M, Nardone A, van Hoek AJ et al. Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016. Euro Surveill. 2017;22(42):pii=17\u201300192. https:\/\/doi.org\/10.2807\/1560-7917.ES.2017.22.42.17-00192.","DOI":"10.2807\/1560-7917.ES.2017.22.42.17-00192"},{"key":"8334_CR50","doi-asserted-by":"publisher","unstructured":"Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T et al. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013\u201317. Lancet HIV 2018; Published online June 6th 2018. https:\/\/doi.org\/10.1016\/S2352:3018(18)30072-9.","DOI":"10.1016\/S2352"},{"issue":"10","key":"8334_CR51","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/S2352-3018(17)30123-6","volume":"4","author":"Rebecca F Baggaley","year":"2017","unstructured":"Baggaley RF, Irvine MA, Leber W, et al. Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis. Lancet HIV 2017; published online July 30. https:\/\/doi.org\/10.1016\/S2352-3018(17)30123-6.","journal-title":"The Lancet HIV"},{"key":"8334_CR52","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/aje\/kwn179","volume":"168","author":"I Jarrin","year":"2008","unstructured":"Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyoz S, Muga R, et al. And the CASCADE collaboration. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV Seroconversion in women. Am J Epid. 2008;168:532\u201340 https:\/\/doi.org\/10.1093\/aje\/kwn179.","journal-title":"Am J Epid"},{"key":"8334_CR53","doi-asserted-by":"crossref","unstructured":"Sagaon-Teysier L, Suzan-Monti M, Demoulin B, Capitant C, Lorente l, Preau M et al. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial. AIDS Care 2016; 28: 48\u201355.","DOI":"10.1080\/09540121.2016.1146653"},{"key":"8334_CR54","unstructured":"Adam P, Alexandre A, de Wit J. Perception de la prophylaxie pr\u00e9-exposition (PrEP) par les internautes gays fran\u00e7ais. http:\/\/www.enipse.fr\/wp-content\/uploads\/2014\/07\/SNEG-IPSR-PREP-Rapport-CapoteEtPilule.pdf. Accessed 19 Apr 2018 (in French)."},{"key":"8334_CR55","doi-asserted-by":"crossref","unstructured":"van Tienen C, van de Vijver D, Noori T, S\u00f6nnerborg A, Boucher C. Letter to the editor: pre-exposure prophylaxis for HIV in Europe: the need for resistance surveillance. Euro Surveill. 2017;22(11):30483.","DOI":"10.2807\/1560-7917.ES.2017.22.11.30483"},{"key":"8334_CR56","doi-asserted-by":"publisher","unstructured":"Marshall BDL, Goedel WC, King MRF, Singleton A, Durham DP, Chan PA et al. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study. Lancet HIV 2018; Published online June 13th 2018. https:\/\/doi.org\/10.1016\/S2352:3018(18)30097-3.","DOI":"10.1016\/S2352:3018(18)30097-3"},{"key":"8334_CR57","unstructured":"Royal Pharmaceutical Society British National Formulary 2016. London: British Medical Association, Royal Pharmaceutical Society; 2016."},{"key":"8334_CR58","unstructured":"WHO. Healthy Adjusted Life Expectancy at Birth. (Mortality and global health estimates). http:\/\/apps.who.int\/gho\/data\/view.main.HALEX.\u00a0Accessed 3 July 2018.\u00a0"},{"key":"8334_CR59","unstructured":"WHO. Health Adjusted Life Expectancy (HALE) at age 60 years. (Mortality and global health estimates). http:\/\/apps.who.int\/gho\/data\/node.imr.WHOSIS_000007?lang=en. Accessed 3 July 2018."},{"issue":"6","key":"8334_CR60","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00038-016-0821-0","volume":"61","author":"Gary M. Ginsberg","year":"2016","unstructured":"Ginsberg G, Block C, Stein-Zamir C. Cost-Utility analysis of a Nationwide Vaccination Program against Serogroup B Meningococcal disease in Israel. International Journal of Public Health, 2016;61;6;683\u2013692. https:\/\/doi.org\/10.1007\/s00038-016-0821-0.","journal-title":"International Journal of Public Health"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-8334-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12889-020-8334-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-8334-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:10:03Z","timestamp":1614298203000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-8334-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["8334"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-8334-4","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"15 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IRB (Helsinki approval) is not required as research is only based on modelling existing data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}